Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Houssein H Ayoub

Showing results (41-50 of 79) with videos related to

Pageof 8
Sort By:
Influenza and Other Respiratory Viruses|September 29, 2024
BNT162b2 Versus mRNA-1273 Vaccines: Comparative Analysis of Long-Term Protection Against SARS-CoV-2 Infection and Severe COVID-19 in QatarHiam Chemaitelly, Houssein H Ayoub, Peter Coyle, et al.
Frontiers in Medicine|March 26, 2024
Addressing bias in the definition of SARS-CoV-2 reinfection: implications for underestimationHiam Chemaitelly, Houssein H Ayoub, Patrick Tang, et al.
Elife|June 9, 2025
Assessing healthy vaccinee effect in COVID-19 vaccine effectiveness studies: a national cohort study in QatarHiam Chemaitelly, Houssein H Ayoub, Peter Coyle, et al.
Scientific Reports|October 8, 2025
Effectiveness and durability of a fourth dose of ancestral-strain mRNA vaccines against SARS-CoV-2 infection: a nationwide matched cohort study in QatarLayan Sukik, Hiam Chemaitelly, Houssein H Ayoub, et al.
BMC Infectious Diseases|August 17, 2025
Effectiveness of ChAdOx1 nCoV-19 (Vaxzevria) primary series vaccine against SARS-CoV-2 beta and delta variants: a nationwide studyHiam Chemaitelly, Houssein H Ayoub, Peter Coyle, et al.
Open Forum Infectious Diseases|March 17, 2025
Evaluating Hospital Admission Data as Indicators of COVID-19 Severity: A National Assessment in QatarLayan Sukik, Hiam Chemaitelly, Houssein H Ayoub, et al.
BMJ Open Respiratory Research|March 26, 2025
Protection conferred by SARS-CoV-2 infection across a spectrum of reinfection symptoms and severitiesLayan Sukik, Hiam Chemaitelly, Houssein H Ayoub, et al.
Eclinicalmedicine|May 3, 2021
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacyLaith J Abu-Raddad, Hiam Chemaitelly, Peter Coyle, et al.
JAMA|November 1, 2021
Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in QatarLaith J Abu-Raddad, Hiam Chemaitelly, Houssein H Ayoub, et al.
Communications Medicine|July 2, 2025
Immune histories and natural infection protection during the omicron eraHiam Chemaitelly, Houssein H Ayoub, Niklas Bobrovitz, et al.
Pageof 8

Showing results (41-50 of 79) with videos related to

Sort By:
Pageof 8
Influenza and Other Respiratory Viruses|September 29, 2024
BNT162b2 Versus mRNA-1273 Vaccines: Comparative Analysis of Long-Term Protection Against SARS-CoV-2 Infection and Severe COVID-19 in QatarHiam Chemaitelly, Houssein H Ayoub, Peter Coyle, et al.
Frontiers in Medicine|March 26, 2024
Addressing bias in the definition of SARS-CoV-2 reinfection: implications for underestimationHiam Chemaitelly, Houssein H Ayoub, Patrick Tang, et al.
Elife|June 9, 2025
Assessing healthy vaccinee effect in COVID-19 vaccine effectiveness studies: a national cohort study in QatarHiam Chemaitelly, Houssein H Ayoub, Peter Coyle, et al.
Scientific Reports|October 8, 2025
Effectiveness and durability of a fourth dose of ancestral-strain mRNA vaccines against SARS-CoV-2 infection: a nationwide matched cohort study in QatarLayan Sukik, Hiam Chemaitelly, Houssein H Ayoub, et al.
BMC Infectious Diseases|August 17, 2025
Effectiveness of ChAdOx1 nCoV-19 (Vaxzevria) primary series vaccine against SARS-CoV-2 beta and delta variants: a nationwide studyHiam Chemaitelly, Houssein H Ayoub, Peter Coyle, et al.
Open Forum Infectious Diseases|March 17, 2025
Evaluating Hospital Admission Data as Indicators of COVID-19 Severity: A National Assessment in QatarLayan Sukik, Hiam Chemaitelly, Houssein H Ayoub, et al.
BMJ Open Respiratory Research|March 26, 2025
Protection conferred by SARS-CoV-2 infection across a spectrum of reinfection symptoms and severitiesLayan Sukik, Hiam Chemaitelly, Houssein H Ayoub, et al.
Eclinicalmedicine|May 3, 2021
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacyLaith J Abu-Raddad, Hiam Chemaitelly, Peter Coyle, et al.
JAMA|November 1, 2021
Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in QatarLaith J Abu-Raddad, Hiam Chemaitelly, Houssein H Ayoub, et al.
Communications Medicine|July 2, 2025
Immune histories and natural infection protection during the omicron eraHiam Chemaitelly, Houssein H Ayoub, Niklas Bobrovitz, et al.
Pageof 8